Newron Pharmaceuticals - Encouraging efficacy data from evenamide trial
Newron has presented new efficacy data from its Phase II evenamide trial (study 014/015) at the CINP World Congress of Neuropsychopharmacology and...
85 Views
Newron Pharmaceuticals - Positive top-line data to support clinical progress
Newron Pharmaceuticals has announced positive top-line results from its Phase II trial (study 014) assessing evenamide, a glutamate modulator, as...
196 Views
Newron Pharmaceuticals - A year ahead of clinical milestones for evenamide
Newron has released its annual report and provided an operational overview for evenamide as a potential schizophrenia therapy. Positive interim...
215 Views
Newron Pharmaceuticals - Evenamide efficacy still going strong after 52 weeks
Newron Pharmaceuticals has announced positive interim results from the first 100 randomised patients completing one year of treatment (77 out of...
290 Views
Newron Pharmaceuticals - Positive interim trial results in schizophrenia
Newron Pharmaceuticals’ share price has responded well to its announcement of encouraging interim efficacy data for the use of evenamide as an...
677 Views